Please login to the form below

Not currently logged in
Email:
Password:

Ziarco appoints Mike Grey to board of directors

He is chairman and CEO of Reneo Pharmaceuticals

Biopharma firm Ziarco, which has a focus on inflammatory skin diseases, has named Mike Grey as an independent director on the company's board.

Grey is chairman and CEO of Reneo Pharmaceuticals, a privately held biotech company, and is additionally a venture partner at Pappas Ventures.

From February 2011 until its acquisition by Shire in May 2014, Grey also served as founder, president and CEO of Lumena Pharma, a biotech focused on developing novel treatments for rare liver diseases.

Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis and psoriasis.

“I look forward to working with the Ziarco team to help grow the company and propel its product candidates forward.”

During his time at Lumena, the company raised $75m, licensed two clinical stage asset and initiated seven phase II studies of its lead compound.

Grey has served as CEO at numerous biopharma companies, including Auspex Pharma, SGZ Pharma and Trega Biosciences. He has also held the role of president at BioChem Therapeutic and president and COO at Ansan.

Ed Mathers, chairman of Ziarco, commented: “We are thrilled to welcome Mike to Ziarco's board of directors. His extensive experience and insight as both a board member and a top-level executive in the biopharma industry will certainly prove invaluable to Ziarco as we advance out lead compounds, ZPL-389 and ZPL-521, through proof-of-concept studies.”

Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.

4th December 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...